Notice2021-28408

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
January 3, 2022

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 1 (Monday, January 3, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 1 (Monday, January 3, 2022)]
[Notices]
[Page 106]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-28408]



[[Page 106]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase 
I: Production of Adjuvants Mimics (Topic 106) (For SBIRs Phase I).
    Date: January 28, 2022.
    Time: 11:00 a.m. to 12:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F52, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Margaret A. Morris Fears, Ph.D., Scientific 
Review Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F52, 
Rockville, MD 20852, (301) 761-5444, <a href="/cdn-cgi/l/email-protection#422f2325252b276c2f2d30302b312427233031022c2b2a6c252d34"><span class="__cf_email__" data-cfemail="234e4244444a460d4e4c51514a504546425150634d4a4b0d444c55">[email&#160;protected]</span></a>.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase 
II: Production of Adjuvants Mimics (Topic 106) (For SBIRs Phase II).
    Date: January 28, 2022.
    Time: 12:30 p.m. to 6:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F52, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Margaret A. Morris Fears, Ph.D., Scientific 
Review Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F52, 
Rockville, MD 20852, (301) 761-5444, <a href="/cdn-cgi/l/email-protection#d0bdb1b7b7b9b5febdbfa2a2b9a3b6b5b1a2a390beb9b8feb7bfa6"><span class="__cf_email__" data-cfemail="86ebe7e1e1efe3a8ebe9f4f4eff5e0e3e7f4f5c6e8efeea8e1e9f0">[email&#160;protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: December 27, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-28408 Filed 12-30-21; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on January 3, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.